US FDA to be stricter on submissions for proprietary name reviews
This article was originally published in SRA
Executive Summary
Companies submitting applications for reviews of their proposed proprietary drug names to the US Food and Drug Administration should expect to see an increase in the number of so-called “incomplete” letters the agency issues in fiscal year 2010. The warning came from Carol Holquist of the FDA’s Center for Drug Evaluation and Research in her presentation at the Drug Information Association’s 45th Annual Meeting in San Diego, US, on 22 June. Karen Finn reports.
You may also be interested in...
Global medtech alliance approves six new member associations
An emerging alliance of medical technology industry associations representing innovative companies that currently develop and manufacture 85% of the world's medical devices, diagnostics and equipment has approved the membership applications of six more associations, bringing the total number of members to 19.
Global medtech alliance approves six new member associations
An emerging alliance of medical technology industry associations representing innovative companies that currently develop and manufacture 85% of the world's medical devices, diagnostics and equipment has approved the membership applications of six more associations, bringing the total number of members to 19.
US FDA scrutiny of DTC genetic tests continues
The US FDA's devices unit has written to three genetic testing companies warning them that they may be marketing their products and services without clearance by the agency.